货号：O1626

储存条件：粉末-20°C可保存3年；液体-80°C可保存12月。

产品描述

DNA damage is an abnormal chemical structure in DNA, while a mutation is a change in the sequence of standard base pairs. Oxaliplatin is an alkylating agent that inhibits DNA synthesis and replication by generating DNA damage. Oxaliplatin can induces immunogenic cell death by provoking the presentation of damage associated molecular patterns. Oxaliplatin inhibited human colorectal tumor cell lines HCT-8, HT-29 and HCT 116 with IC₅₀ values of 0.87 μM, 0.88 μM and 0.53 μM, respectively. Oxaliplatin inhibited human bladder cancer cell lines TCC SUP and RT-4 with IC₅₀ values of 15.04 and 11.10 μM, respectively. Oxaliplatin inhibited human Glioma cell lines U-87MG and U-373MG with IC₅₀ values of 17.60 and 2.95 μM, respectively. Furthermore, oxaliplatin could active mTOR pathway via increasing the level of phosphorylated p70 S6 kinase in five ATCC cell lines HCT15, DLD-1, LoVo, HCT116, HT29 and Colo 205. In vivo, administration of 10 mg/kg Oxaliplatin via tail vein injection once a week for 4 weeks significantly inhibited the MHCC97 cells subcutaneously tumor. Treatment with Oxaliplatin at the dose of 10 mg/kg once a week for 4 weeks inhibited the growth of human hepatocellular HCCLM3 xenografts in nude mice. Treatment with oxaliplatin at the dose of 10 mg/kg induced mTOR activation and immunogenic cell death in colon cancer xenografts model. In early clinical, oxaliplatin demonstrated clinical activity in a variety of tumors, including CRC, breast, endometrial cancers and malignant melanoma.

产品信息